Concepedia

James Wassil

JW

Statistics

Publications

4

Citations

105

H-Index

4

Active since

2013

Affiliations

Incyte (United States)(Current)

James Wassil is an author at Incyte (United States) specializing in vaccination, infectious diseases, and vaccinology.

Publications per year

2013–2024

4

Publications

4

Non-clinical immunological comparison of a Next-Generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23)

Jeff Fairman, Paresh Agarwal, Sandrine Barbanel et al. · Vaccine · 2021 · 51 citations · Full text

, , +17

Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trial

James Wassil, Maggie Sisti, Jeff Fairman et al. · The Lancet Infectious Diseases · 2023 · 31 citations

, , +17

Modelled evaluation of multi-component meningococcal vaccine (Bexsero<sup>®</sup>) for the prevention of invasive meningococcal disease in infants and adolescents in the UK

Jasper Huels, Karen M. Clements, Lisa J. McGarry et al. · Epidemiology and Infection · 2013 · 13 citations · Full text

, , +17

A phase 2, randomized, blinded, dose-finding, controlled clinical trial to evaluate the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults 65 years and older

James Wassil, Massimo Sisti, Jeff Fairman et al. · Vaccine · 2024 · 10 citations · Full text

, , +17

1–4 of 4